CANF | tickerfilter.com

Fundamental analysis

26%

Profitability 25%

Dept financing 12%

Liquidity 46%

Performance 25%

Company vs Stock growth

+ Add row to compare

Performance

5 Days

-2.05%

1 Month

-30.24%

3 Months

-30.24%

6 Months

-46.04%

1 Year

-33.18%

2 Year

-77.66%

Key data

Stock price

$1.50

P/E Ratio

0.00

DAY RANGE

$1.46 - $1.48

EPS

$0.00

52 WEEK RANGE

$1.41 - $4.69

52 WEEK CHANGE

-$32.55

MARKET CAP

3.422 M

YIELD

N/A

SHARES OUTSTANDING

1.541 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.89

PUBLIC FLOAT

AVERAGE 10 VOLUME

$223,908

AVERAGE 30 VOLUME

$1,189,048

Company detail

CEO: Pnina Fishman
Region: US
Website: canfite.com
Employees: 8
IPO year: -

Issue type: American Depository Receipt (ADR’s)
Market: NYSE American
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

Can-Fite BioPharma Ltd. develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the. treatment of psoriasis; and Phase II clinical trials for COVID-19. It also develops Namodenoson that is in Phase III. trial for. hepatocellular carcinoma, as well as in Phase IIb trial for treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial.

CANF - Can-Fite BioPharma Ltd.